Malaria remains a significant contributor to the global burden of disease, with around 40% of
the world's population at risk of Plasmodium infections. The development of an effective …

Malaria—a parasite vector-borne disease—is a global health problem, and Plasmodium
falciparum has proven to be the deadliest among Plasmodium spp., which causes malaria in …

Radical control of malaria likely requires a vaccine that targets both the asymptomatic liver
stages and the disease-causing blood stages of the human malaria parasite Plasmodium …

Malaria and schistosomiasis are two major parasitic diseases that remain leading causes of
morbidity and mortality worldwide. Co-infections of these two parasites are common in the …

Emergence and re-emergence of pathogens bearing the risk of becoming a pandemic threat
are on the rise. Increased travel and trade, growing population density, changes in …

Extensive control efforts have significantly reduced malaria cases and deaths over the past
two decades, but in recent years, coupled with the COVID-19 pandemic, success has …

Introduction: An effective vaccine against malaria forms a global health priority. Both
naturally acquired immunity and sterile protection induced by irradiated sporozoite …

The merozoite surface protein 1 (MSP-1) is the most abundant protein on the surface of the
erythrocyte-invading Plasmodium merozoite, the causative agent of malaria. MSP-1 is …

Plasmodium sporozoite development in and egress from oocysts in the Anopheles mosquito
remains largely enigmatic. In a previously performed high‐throughput knockout screen, the …

Defining mechanisms of pathogen immune evasion and neutralization are critical to develop
potent vaccines and therapies. Merozoite Surface Protein 1 (MSP-1) is a malaria vaccine …